logo-loader
viewGnomegen LLC

Gnomegen hopes to achieve early detection of cancer relapse with its liquid biopsy tools

Gnomegen LLC President and CSO Yan Wang sat down with Proactive’s Christine Corrado at BIO CEO & Investor Conference in New York. The company is advancing its real-time digital polymerase chain reaction (PCR) assays for cancer companion diagnostics, as well as its digital PCR instrument. The company hopes to achieve early detection of relapse and progression of cancer with its liquid biopsy tools.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: GlobeX Data begins a social media influencers program for...

GlobeX Data (OTCQB: SWISF- CSE: SWIS) CEO Alain Ghiai joined Steve Darling from Proactive Vancouver with news the company has started a social media influencers program to help get the word out about their cybersecurity products. Ghiai telling Proactive how the program will work and the...

5 hours, 20 minutes ago

2 min read